Volume 7 Supplement 2

13th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Joint Meeting with the Austrian Society of Toxicology (ASTOX) and the Hungarian Society for Experimental and Clinical Pharmacology (MFT)

Open Access

GPR55 is a novel cannabinoid receptor

BMC Pharmacology20077(Suppl 2):A3

https://doi.org/10.1186/1471-2210-7-S2-A3

Published: 14 November 2007

Cannabinoids exert their effects by binding to G protein-coupled receptors (GPCRs). To date, two cannabinoid receptors have been cloned. The cannabinoid CB1 receptor is one of the most abundant GPCRs in the central nervous system and plays an important role in pain transmission, feeding and the rewarding effects of cannabis, whereas the CB2 receptor is predominantly found in immune cells. However, some effects of cannabinoids (especially in the vascular system) could not be attributed to either CB1 or CB2 receptor function. Here we present GPR55 as a putative novel cannabinoid receptor, since GPR55 signals, binds to and internalizes in the presence of synthetic cannabinoid ligands.

Authors’ Affiliations

(1)
Department of Experimental and Clinical Pharmacology, Medical University of Graz
(2)
Neurosciences Institute, Division of Pathology and Neuroscience, University of Dundee

Copyright

© Balenga et al; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd.

Advertisement